Context: Somatostatin analogs have been successfully used to treat patients with GHsecreting pituitary adenomas as they are safe, effective and usually welltolerated . Results of studies evaluating acromegaly treatment with the somatostatin receptor ligands (SRLs), octreotide and lanreotide, have supported the use of these agents for primary medical therapy prior to, or as an alternative to traditional interventions of surgery and radiotherapy in selected cases.
Evidence Acquisition: We therefore undertook a systematic literature overview to characterize results of studies involving primary therapy with somatostatin analogues and their effects on pituitary tumor size.Since most studies in which pituitary tumor shrinkage has been assessed involve uncontrolled, open-label prospective trials or retrospective case series, the lack of a control arm does not permit pooling of data in a meta-analytic fashion to determine tumor size reduction. Therefore, this systematic review was designed to document and stratify data by study design, to summarize therapeutic regimens and patient characteristics, and to assess the percentage of patients showing changes in tumor size and, to calculate the weighted average effect on size reduction .
Evidence Synthesis: Overall, for patients who experience significant shrinkage, a ~50% decrease in pituitary mass is achieved when a somatostatin analog is used exclusively or prior to surgery or radiotherapy. Fourteen studies (N=424) provided a definition of tumor shrinkage and results showed that 36. 62% (weighted mean percent) of patients receiving primary SRL therapy for acromegaly experienced a significant reduction in tumor size.The weighted mean percent reduction in tumor size was 19.4%.
Conclusions: Clinical implications are discussed for patients in whom tumor size control with SRL's is an important objective, typically those who have failed surgery or are treated with primary medical therapy with large tumors.
INTRODUCTION:
Somatostatin analogs have been successfully used to treat patients with GH-secreting pituitary adenomas as they are safe, effective and in the majority of patients, usually welltolerated (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Although these analogs are approved for use after non-curative pituitary surgery, wider experience has led to recommendations for their primary use in selected patients newly diagnosed with acromegaly. Factors influencing the primary use of somatostatin analogs include low cure rates achieved after surgical resection for pituitary macroadenomas with persistent post-operative growth hormone (GH) hypersecretion especially with cavernous sinus invasion, wide variability in surgical experience and skill, prevalence of peri-operative side effects, unacceptable anesthetic risk for some patients, and refusal of surgery.
Results of studies evaluating acromegaly treatment with the somatostatin receptor ligands (SRLs), octreotide and lanreotide, have supported the use of these agents for primary medical therapy prior to, or as an alternative to traditional interventions of surgery and radiotherapy in selected cases. The effect of medical therapy on tumor mass is an important consideration. Several clinical trials have reported changes in tumor size associated with various somatostatin analog regimens in treating GH-secreting pituitary tumors. Patient populations in these studies were either previously treated, previously untreated, or drawn from both categories. Several authors, typically in narrative reviews, have summarized results of trials regarding pituitary tumor shrinkage, either as a result of therapy with somatostatin analog before or after other therapies or, less frequently, when used naively as primary therapy. However, a comprehensive review of all such studies on tumor size has not been reported.
We therefore undertook a systematic literature overview to update, aggregate, and characterize the results of studies involving primary therapy with somatostatin analogues and their effects on pituitary tumor size. A separate review of primary therapy using dopamine agonists was also undertaken. Since most studies in which pituitary tumor shrinkage has been assessed typically involve uncontrolled, open-label prospective trials or retrospective case series, the lack of a control arm does not permit the pooling of data in a meta-analytic fashion to determine tumor size reduction. Therefore, this systematic review was designed to document and stratify data by study design, to summarize therapeutic regimens and patient characteristics, and to assess the percentage of patients showing changes in tumor size and, when possible, to calculate the weighted average effect on size reduction in the treatments groups. Clinical implications are discussed for patients in whom tumor size control is an important objective, typically those who have failed surgery or are treated with primary medical therapy with large residual tumors.
METHODS

Article Identification
The peer-reviewed medical literature was searched to identify clinical trials potentially eligible for systematic review. Trials studying pituitary tumor size as an outcome of somatostatin treatment of acromegaly were identified through 2004 using online bibliographic PubMed database search strategies, and reference lists from selected textbooks and retrieved articles.
Inclusion Criteria
To be included in this analysis, studies had to be published in English language, peerreviewed medical journals, having any of the following designs: randomized controlled trial, prospective, non-randomized trial, retrospective study, case report, or case series.
The study populations comprised patients with diagnosed acromegaly resulting from growth-hormone secreting pituitary adenomas. To be included, patients must not have been treated previously with either radiotherapy or surgery; however, prior treatment with dopamine agonists or somatostatin analog was not a reason for exclusion.
The therapeutic interventions used in these studies needed to include administration of one or more somatostatin analogs as primary therapy, or as therapy prior to surgery or radiotherapy. The somatostatin analog evaluated were octreotide, octreotide long-acting release (LAR), lanreotide, or lanreotide sustained release (SR). One of the stated study outcomes required change in pituitary tumor size evaluated by magnetic resonance imaging (MRI) in all or in a majority of patients. Because CT scanning has been shown to be less precise than MRI in measuring the size and mass of pituitary tumors, studies primarily using computed tomography (CT) scanning were excluded from analysis.
RESULTS
Article Selection
We identified 693 studies that evaluated somatostatin analog treatment for acromegaly.
Of these, 15 were found to be eligible for study after applying inclusion and exclusion criteria (1, 6, 7, 11, 15) , 9 studies employed tumor volume calculations 2-6, 8-10, 12, 14) and in 1 study, the measurement method was not described (13) .
Tumor size effects
Fourteen studies (N=424) provided a definition of tumor shrinkage and described the percentage of patients receiving an SRL that demonstrated a significant shrinkage in tumor size ( Table 5 Seven studies (N=70) provided tumor shrinkage data for those patients who responded to treatment and met investigators' various criteria for displaying "significant shrinkage" (Table 6 ). The weighted mean percent significant reduction in tumor size for this group of responders was 49.8%. This figure was calculated by adding the sum of the products for a). the percentage significant shrinkage in each study times b). the number of patients responding with significant shrinkage in that study divided by c). the total number of patients with significant shrinkage from all 7 studies. This percentage was not different between patients who received short-acting octreotide (49.5%) and those who received long-acting preparations (50%).
Three studies (N=151) provided tumor shrinkage data for all study patients receiving an SRL in the study whether or not their tumors underwent shrinkage ( Table 7) . The weighted mean percent reduction in tumor size for this group was 19.4%. The mean percent reduction in tumor size for those patients receiving long-acting preparations was 13.4%.
Specific assumptions were used for calculating the weighted mean percent of patients with shrinkage and weighted mean percent shrinkages. These assumptions were that heterogeneity of study designs and calculation methods were not to be considered, that all individual percentages were to be used, irrespective of study criteria for significant shrinkage, and that the midpoint value was to be used when two percentages were provided.
Primary therapy with dopamine agonists
Twenty-six studies were identified that evaluated the effect of dopamine agonist therapy for acromegaly on tumor size, of which 5 fulfilled inclusion criteria (16) (17) (18) (19) (20) . A review of the reference lists of the 5 retrieved citations suggested the possibility of 5 additional citations. These were reviewed, and 3 were excluded because either patients receiving primary therapy were not specifically identified when tumor shrinkage was quantified, or because a majority of the tumors studied secreted hormones other than growth hormone.
Two additional citations (21, 22) were retained. Review of these 7 studies including primary therapy with dopamine agonists for acromegaly indicates that tumor shrinkage has been documented in approximately 4-5% of patients.
DISCUSSION
Several studies have reported the efficacy of long-acting somatostatin analogs in achieving biochemical and clinical control of patients with acromegaly either as adjuvant or primary therapy (Reviewed in [23] [24] [25] [26] . Reports of drug effects on tumor size are limited by lack of rigor in study design, heterogenous imaging techniques and measurements, and lack of controls. Nevertheless, except for 1 study (1) persistent tumor growth has generally not been observed in patients receiving SRL therapy. Furthermore, when somatostatin analogs are discontinued, tumor regrowth appears to occur within 6 months (27) . In our review, no randomized placebo-controlled trials measuring tumor size change following SRL therapy were identified, as a result of which a true metaanalysis could not be performed. However, this critical literature analysis shows that overall, for patients who experience significant shrinkage as variously defined by different investigators, a ~50% decrease in pituitary mass is achieved when a somatostatin analog is used exclusively or prior to surgery or radiotherapy. Absent a random placebo-controlled trial, a true meta-analysis could not be performed.
Importantly, the initial pre-treatment tumor size is a determinant of the significance of measured shrinkage. For example, one dimension shrinkage of a 10 mm diameter mass to 5 mm (i.e. 50%) is clearly of greater clinical significance than a 50% shrinkage of a 4 mm well-circumscribed intrasellar micro-adenoma. In contrast, using a 3 dimensional measurement, shrinkage of this mass may be reported as 87%.A limitation inherent in this analysis is lack of independent review of the primary MRI data and reliance on published scan readings.
Clinical benfits of tumor mass shrinkage include relief of vital structure impingement, patient re-assurance that the mass is shrinking,and possibly a lowered risk of intratumoral hemorrhage. Surgery is the first-line therapy for well-circumscribed micro-adenomas, and medical therapy is indicated should surgery not be curative (28) (29) . Primary SRL therapy may be offered in selected patients with unacceptable anaesthetic risk, cardiovascular or pulmonary complications, (30) and macroadenomas not impinging on the optic chiasm, with little likelihood of surgical cure. Because the majority of patients with macroadenomas, especially those with tumors extending into the cavernous sinus, will not be cured surgically, post-operative therapy is required in most patients. For those patients with persistent GH hypersecretion and visible tumor on MRI which suggests the probability of cure, re-operation, by an experienced pituitary surgeon following initial surgery by an inexperienced surgeon, is recommended (31) . No controlled prospective data are currently available on the value of non-curative debulking surgery.Medical therapy options include the use of dopamine agonists, SRL therapy and pegvisomant (32) . Overall, only a small percent of patients, usually those with only minimal IGF-I elevations will be controlled by dopamine agonists. For patients with significant residual tumor mass in whom tumor control is clinically indicated, and for whom repeat surgery is not an efficacious option, SRL therapy is indicated. As the overall maximal efficacy of SRL therapy is ~70%, a significant minority of patients can be expected to have persistent hormone hypersecretion. If control is inadequately achieved with maximal SRL doses and added dopamine agonists, or if patients are intolerant of SRLs, therapy should be initiated with pegvisomant, the GH receptor antagonist, sometimes in the setting of radiation therapy (33) . The advantage of SRL is tumor control; the advantage of pegvisomant is near 100 percent IGF-I normalization. In patients who have failed both surgical and optimal medical therapy, or who have evidence of continued tumor growth while receiving medical therapy, radiotherapy should be considered, depending on clinical disease activity and the degree or persistence of biochemical disease.
As potential adverse effects limit the efficacy of treatments for acromegaly, integrated treatment decisions are best by a made by a team that includes endocrinologists and surgeons. Long-term treatment cost is also a significant determinant of therapeutic choice. The ultimate choice of therapy should be based upon an informed patient understanding of the potential disadvantages of therapeutic approaches versus their effectiveness in managing a complex metabolic disorder, by reducing its co-morbidities, and by ultimately achieving favorable mortality outcomes (34, 35) . 
No randomized placebo-controlled trials measuring tumor size change following primary therapy were identified. 
